Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    CAR-TCR Global 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

COVID-19

Learnings from the COVID-19 pandemic for the advanced therapies sector 2:04
Learnings from the COVID-19 pandemic for the advanced therapies sector
Miguel Forte • 5 Oct 2021
Driving the development of gene therapies for more common conditions 3:00
Driving the development of gene therapies for more common conditions
Paul Gissen • 6 Oct 2021
Promising avenues in extracellular vesicle-based therapeutics 5:05
Promising avenues in extracellular vesicle-based therapeutics
Eva Rohde • 10 Jun 2021
Tackling unproven cell-based therapies and the impact of COVID-19 7:29
Tackling unproven cell-based therapies and the impact of COVID-19
Aaron Levine • 28 May 2021
The potential of oncolytic adenoviral vectors 1:32
The potential of oncolytic adenoviral vectors
Margarita Romanenko • 13 May 2021
AVA-Trap blood filtration for cytokine storm in COVID-19 6:26
AVA-Trap blood filtration for cytokine storm in COVID-19
Shuguang Zhang • 17 Jun 2021
What can CGT manufacturing learn from the COVID-19 pandemic? 6:15
What can CGT manufacturing learn from the COVID-19 pandemic?
Delara Motlagh • 1 Jun 2021
The state of investment in cell & gene therapy 3:31
The state of investment in cell & gene therapy
Matthew Durdy • 9 Apr 2021
What can the field learn from the COVID-19 pandemic? 2:45
What can the field learn from the COVID-19 pandemic?
Amy DuRoss • 8 Apr 2021
The lasting impact of COVID-19 on the CGT sector 3:10
The lasting impact of COVID-19 on the CGT sector
Stephen Ward • 14 Apr 2021
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004 4:54
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004
Miguel Forte • 26 May 2021
Anticipating a crackdown on unproven cell-based therapies 4:09
Anticipating a crackdown on unproven cell-based therapies
Laertis Ikonomou • 25 May 2021
Exosomes: a game changer in mRNA-based therapeutics? 1:19
Exosomes: a game changer in mRNA-based therapeutics?
Linda Marban • 19 May 2021
Exosome-based mRNA vaccines against SARS-CoV-2 2:07
Exosome-based mRNA vaccines against SARS-CoV-2
Linda Marban • 19 May 2021
The impact of COVID-19 on validating cell therapy products 1:40
The impact of COVID-19 on validating cell therapy products
Bruce Levine • 11 Mar 2021
What to expect at ISCT 2021 1:50
What to expect at ISCT 2021
Bruce Levine • 11 Mar 2021
  • Previous
  • 1
  • 2
  • 3
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy